Sunshine Biopharma (Sunshine Biopharma) Float Percentage Of Total Shares Outstanding : 96.30% (As of May. 17, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sunshine Biopharma's float shares is 0.95 Mil. Sunshine Biopharma's total shares outstanding is 0.99 Mil. Sunshine Biopharma's float percentage of total shares outstanding is 96.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sunshine Biopharma's Insider Ownership is 24.07%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sunshine Biopharma's Institutional Ownership is 0.31%.

Sunshine Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Sunshine Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.95	/	0.99
	=	96.30%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Executives

Camille Sebaaly	director, officer: CFO and Secretary	14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun	10 percent owner	1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller	director	10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey	director	6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish	director	6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah	director	924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp	10 percent owner	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty	director, 10 percent owner, officer: CEO and President	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki	director, officer: Chief Operating Officer	731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di	director, officer: Chief Operating Officer	3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3